Drug Guidance for Subsidy 02/07/2018 LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD) The Ministry of Health’s Drug Advisory Committee has recommended: Umeclidinium 62.5mcg inhal... See all × 02/07/2018 LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD) The Ministry of Health’s Drug Advisory Committee has recommended: Umeclidinium 62.5mcg inhalation powder for the: Maintenance treatment of patients diagnosed by spirometry with chronic obstructive pulmonary disease (Group B or C) who have breathlessness. Umeclidinium/vilanterol 62.5/25mcg inhalation powder for the: Maintenance treatment of patients diagnosed by spirometry with chronic obstructive pulmonary disease (Group B or C) who have frequent exacerbations (at least 2 per year or at least 1 leading to hospitalisation per year) and/or persistent breathlessness despite treatment with LAMA monotherapy. Maintenance treatment of patients diagnosed by spirometry with chronic obstructive pulmonary disease (Group D) with persistent symptoms and frequent exacerbations. Subsidy status RUmeclidinium 62.5mcg inhalation powder and umeclidinium/vilanterol 62.5/25mcg inhalation powder are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications. NRSDL subsidies do not apply to the following: Other LAMAs (glycopyrronium, tiotropium or aclidinium) Other LAMA/LABAs (indacaterol/glycopyrronium, tiotropium/olodaterol or aclidinium/formoterol)
BUCCAL Select a brand starting with the letter: S SEEBRI BREEZHALER INHALATION POWDER, HARD CAPSULE 50MCG [SIN14431P]